A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Incyte Corporation
- 24 Oct 2017 Status changed from planning to not yet recruiting.
- 04 May 2017 According to an Incyte Corporation media release, this trial is expected to initiate in 2017.
- 07 Apr 2017 New trial record